Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

NowRX Puts Pharmacists in a Warehouse and Employees Making the Delivery

By Dana Blankenhorn, InvestorPlace Contributor

Right now NowRX is only operating in California, where it has delivered 150,000 prescriptions to 18,000 customers. But it has nationwide ambitions.

Luckin Coffee Stock Represents the Rising Cost of Market Fraud

By Dana Blankenhorn, InvestorPlace Contributor

Luckin Coffee's instance of fraud isn't unheard of it, but it makes LK stock the perfect target for American trade hawks.

Enphase Gives Solar Stocks Hope Once Again

By Dana Blankenhorn, InvestorPlace Contributor

Solar stocks are once again shining bright thanks to inverter technology from Enphase Energy. Profits will soon be brighter than the sun.

Target Finds a Downside in Its Urban Strategy

By Dana Blankenhorn, InvestorPlace Contributor

Target stock fell after some of its stores were looted, while others are now closed. But its urban strategy remains sound for the long term.

Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk

By Dana Blankenhorn, InvestorPlace Contributor

Analysts call ABBV stock a bargain after its $63 billion purchase of Allergan, whose existing drugs and pipeline are now expected to replace revenue from Humira.

Load More